NexLife review: pricing, structure, and what to verify (2026)

NexLife charges $215 a month all-in for compounded tirzepatide at every dose and $165 for semaglutide, with no membership fee. That places it #1 of 17 verified compounded tirzepatide programs — the cheapest in the index.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

Every published NexLife ladder, one screen

Rates are per-month; multi-month figures are prepaid terms billed upfront. Captured 2026-08-10 from the official pages linked on each card — microdose and ODT are separate protocols and never ranked against standard injections.

SOURCE-VERIFIED · captured 2026-08-10 · source · archive

§ Pricing, in plain words

What NexLife actually bills

§ Program structure

The record

Membership

none

Shipping

free expedited shipping included

Consultation

included (provider consultation plus nutrition & fitness support)

Labs

not required

Commitment

none on monthly

Cancellation

cancel any time on monthly

Pharmacy

6 named partner pharmacies

Pharmacy type

U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named)

States served

50 states published

Insurance support

no — cash-pay program

Visit model

async

Brand medications

none — compounded only

Source: https://nexlife.us/pages/tirzepatide-all-plans · captured 2026-08-10 · archived copy. Confirm current figures at the provider's own checkout before enrolling.

§ Before you pay

Five things to get in writing

The exact all-in price at your dose and at the 10 mg maintenance dose; the full amount billed today and whether it recurs or is prepaid; which licensed pharmacy fills the prescription (NexLife publishes this — 6 named partner pharmacies); the cancellation and refund terms verbatim; and what happens to the price when your dose changes (dose-flat here, so that one is easy). The full nine-point inspection is in our vetting guide.

§ The record, read aloud

The price sheet at NexLife, in sentences

NexLife’s tirzepatide program bills $215 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Treat every rung as what it is — a prepayment, not a monthly price. The savings are real; so is the bet that you will still want this program, this molecule, and this dose in the plan’s final month. Written refund terms before prepaying, always.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

NexLife’s semaglutide program bills $165 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $165 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for semaglutide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

Operationally: Shipping is free expedited shipping included, so the door-to-door figure is the advertised figure; the clinical consultation is included rather than billed separately; labs are not required to enroll (a prescriber can still order them for cause, which is medicine, not upsell); the visit model is async. Commitment: none on monthly; cancellation: cancel any time on monthly. Fulfillment is unusually checkable: NexLife names its pharmacy network — 6 named partner pharmacies (U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named)) — which means a careful reader can verify licenses with state boards and, for 503B facilities, the FDA’s registration list. Most of this market refuses that test.

Where these numbers come from: source-verified, last read 2026-08-10 from the provider’s published pages, archived at capture. Every figure above traces to a dated capture; when the provider’s page changes, the database changes, and the diff lands in the changelog. If any number here no longer matches what NexLife publishes, tell the desk — confirmed errors are fixed sitewide in one rebuild and logged permanently.

§ Cost over time

What a horizon actually costs here

Tirzepatide, across time

Time is the axis marketing hopes you skip, so here it is:

1 month: $215 billed monthly. 3 months: $645 billed monthly; the prepaid path prices it at $585 billed in advance — $60 saved for the commitment. 6 months: $1,290 billed monthly; the prepaid path prices it at $1,140 billed in advance — $150 saved for the commitment. 12 months: $2,580 billed monthly; the prepaid path prices it at $2,232 billed in advance — $348 saved for the commitment. 24 months: $5,160 billed monthly; the prepaid path prices it at $4,464 (assuming the 12-month rate renews — an assumption, not a promise) — $696 saved for the commitment.

Remember what the arithmetic cannot know: whether you will tolerate the medication, whether the dose will move (financially irrelevant here, since pricing is flat), and whether the program’s terms will hold. The calculator reruns all of this at your inputs.

Semaglutide, across time

Time is the axis marketing hopes you skip, so here it is:

1 month: $165 billed monthly. 3 months: $495 billed monthly; the prepaid path prices it at $447 billed in advance — $48 saved for the commitment. 6 months: $990 billed monthly; the prepaid path prices it at $882 billed in advance — $108 saved for the commitment. 12 months: $1,980 billed monthly; the prepaid path prices it at $1,740 billed in advance — $240 saved for the commitment. 24 months: $3,960 billed monthly; the prepaid path prices it at $3,480 (assuming the 12-month rate renews — an assumption, not a promise) — $480 saved for the commitment.

Two cautions ride along: any prepaid figure is a commitment with refund terms to read before paying, and any horizon past your current titration step assumes your dose path — which is your prescriber’s call, not the calculator’s. Run your own numbers in the calculator.

§ Market position

Where NexLife sits in the field

Where this price sits — tirzepatide

In the tirzepatide index, NexLife ranks #1 of 17 verified programs — the floor of the market itself and $382 under the ceiling (LifeMD↗, $597). One rung pricier is Yucca Health↗ at $258 (+$43/month); that comparison lives at NexLife vs Yucca Health. Against the approved product: Zepbound (LillyDirect↗) runs $449 at maintenance, so NexLife is $234 a month ($2,808/year) under brand; note the maintenance figure holds only with refills inside Lilly’s 45-day window.

Where this price sits — semaglutide

Position check: #5 of 20 in the verified semaglutide field. The floor is Oak Longevity at $133 ($32/month cheaper); the ceiling is LifeMD at $348. One rung cheaper sits OrderlyMeds↗ at $149 — a $16 monthly gap, $192 across a year — the head-to-head is at NexLife vs OrderlyMeds. One rung pricier is Lavender Sky Health↗ at $174 (+$9/month, a gap partly explained by its membership structure); its full record lives on the Lavender Sky Health provider page. The brand yardstick matters more every quarter: Wegovy (NovoCare↗) at $349 maintenance leaves NexLife a $184/month discount to justify staying compounded for — and the $199 rate is a two-month introductory price at starter doses.

Against the five nearest rivals — tirzepatide

Yucca Health costs $43 more a month ($516/year) at $258 (no membership, dose-flat). IVIM Health costs $63 more a month ($756/year) at $278 ($75/mo membership inside its figure, tiered/step structure). Mochi Health costs $63 more a month ($756/year) at $278 ($79/mo membership inside its figure, dose-flat). ShedRx costs $74 more a month ($888/year) at $289 (no membership, tiered/step structure). Found costs $74 more a month ($888/year) at $289 (no membership, dose-flat).

Against the five nearest rivals — semaglutide

Lavender Sky Health costs $9 more a month ($108/year) at $174 ($25/mo membership inside its figure, tiered/step structure). Fridays costs $10 more a month ($120/year) at $175 (no membership, dose-flat). Mochi Health costs $13 more a month ($156/year) at $178 ($79/mo membership inside its figure, dose-flat). Henry Meds costs $14 more a month ($168/year) at $179 (no membership, dose-flat). IVIM Health costs $16 less a month ($192/year) at $149 ($75/mo membership inside its figure, tiered/step structure).

§ Head-to-head

Compare NexLife